Hematology

Both parties obtain “substantial freedom” to conduct research under certain of each other’s IP and develop therapeutic, prophylactic and diagnostic products.

Agreement to be acquired by Switch Pharma Ltd. expected to close on Sept. 30, subject to requisite approvals.

Advances in genomics, proteomics, and metabolomics over the last decade have provided an unprecedented, exquisitely detailed view into the molecular nature of disease and treatment. Biomarkers are among the most practical tools arising from the “omics” revolution.

DiscoveRx Corp., which thus far has been known primarily for being the provider of the off-the-shelf HitHunter assays, has made things personal—or at least personalized—by launching custom labeling and profiling services.

PerkinElmer has expanded and deepened its screening and diagnostics offerings with the acquisition of Spectral Genomics’ assets for molecular karyotyping technology used to evaluate chromosomal abnormalities.

The difference between a salve and a poison can be simply a question of dose.

In a deal worth potentially just over a half billion dollars, SGX Pharmaceuticals is embarking on a license and collaboration agreement with Novartis that focuses on the development and commercialization of BCR-ABL inhibitors for the treatment of drug resistant chronic myelogenous leukemia (CML).

Illumina inks a nearly $7 million contract to conduct large-scale genotyping for United Kingdom-based research groups that are studying the molecular basis of prostate cancer.

LOS ANGELES—Cedars-Sinai Medical Center’s Maxine Dunitz Neurosurgical Institute recently developed a tool to track and kill malignant brain tumor cells

SuperGen Inc. has entered into a definitive agreement to acquire Montigen Pharmaceuticals Inc., a privately held oncology-focused drug discovery and development company based in Salt Lake City.